A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-29. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
=== Structure === X-ray structures of DPP-4 that have been published since 2003 give rather detailed information about the structural characteristics of the binding site. Many structurally diverse DPP-4 inhibitors have been discovered and it is not that surprising considering the properties of the binding site: 1. A deep lipophilic pocket combined with several exposed aromatic side chains for achieving high affinity small molecule binding. 2. A significant solvent access that makes it possible to tune the physico-chemical properties of the inhibitors that leads to better pharmacokinetic behavior. DPP-4 is a 766-amino acid transmembrane glycoprotein that belongs to the prolyloligopeptidase family. It consists of three parts; a cytoplasmic tail, a transmembrane region and an extracellular part. The extracellular part is divided into a catalytic domain and an eight-bladed β-propeller domain. The latter contributes to the inhibitor binding site. The catalytic domain shows an α/β-hydrolase fold and contains the catalytic triad Ser630 - Asp708 - His740. The S1-pocket is very hydrophobic and is composed of the side chains: Tyr631, Val656, Trp662, Tyr666 and Val711. Existing X-ray structures show that there is not much difference in size and shape of the pocket that indicates that the S1-pocket has high specificity for proline residues
Viola, commonly known as the violets, is a genus of flowering plants in the family Violaceae. It is the largest genus in the family, containing over 680 species. Most species are found in the temperate Northern Hemisphere; however, some are also found in widely divergent areas such as Hawaii, Australasia, and the Andes. Some Viola species are perennial plants, some are annual plants, and a few are small shrubs. Many species, varieties and cultivars are grown in gardens for their ornamental flowers. In horticulture, the term pansy is normally used for those multi-colored large-flowered cultivars which are raised annually or biennially from seed and used extensively in bedding.
Shotgun sequencing is a sequencing method designed for analysis of DNA sequences longer than 1000 base pairs, up to and including entire chromosomes. This method requires the target DNA to be broken into random fragments. After sequencing individual fragments using the chain termination method, the sequences can be reassembled on the basis of their overlapping regions. This method was heavily used in the Human Genome Project.
Sources: en.wikipedia.org
=== NSAIDs === Unless otherwise contraindicated, all people with AS are recommended to take non-steroidal anti-inflammatory drugs (NSAIDs). The dose, frequency, and specific drug may depend on the individual and the symptoms they experience. NSAIDs, such as ibuprofen and naproxen, are used to alleviate pain, reduce inflammation, and improve joint stiffness associated with AS. These medications work by inhibiting the activity of cyclooxygenase (COX) enzymes, which are involved in the production of inflammatory prostaglandins. By reducing the levels of prostaglandins, NSAIDs help mitigate the inflammatory response and relieve symptoms in individuals with ankylosing spondylitis.
Cupuaçu trees usually range from 5–15 m (16–49 ft) in height, though some can reach 20 m (66 ft). They have brown bark, and the leaves range from 25–35 cm (9.8–13.8 in) long and 6–10 cm (2.4–3.9 in) across, with 9 or 10 pairs of veins. As the trees mature, the leaves change from pink-tinted to green, and eventually they begin bearing fruit. Flowers of cupuaçu are structurally complex, and require pollination from biotic vectors. The majority of cupuaçu trees are self-incompatible, which can result in decreased pollination levels, and consequently, a decrease in fruit yields. Pollination can also be negatively affected by environmental conditions. Pollinators, which include chrysomelid weevils and stingless bees, are unable to fly between flowers in heavy rains.
The youth set-up did not replicate the success of the late 1990s and early 2000s, though Arsenal consistently finished fourth or higher in the league between 2006 and 2011. The club earnt a reputation of functioning as a "feeder club" to bigger teams, as Wenger struggled to keep hold of his best players. He described this period as "very sensitive" because of the financial restrictions that came with the stadium move. Since the 2011–12 season, Wenger has reverted to buying proven talent, and blended experience with youth in domestic cup competitions. Arsenal have benefited from increased revenue since the Emirates move, and negotiating new sponsorship deals has allowed Wenger to make marquee signings such as Özil, Sánchez, Granit Xhaka, Alexandre Lacazette and Pierre-Emerick Aubameyang. Observing Wenger's transfer policy in 2009, Sir Alex Ferguson commented that it lacked balance and needed defensive players to solidify the Arsenal team. The players Wenger recruits have often been criticised for their character and leadership capabilities; footballer Joey Barton suggested it was because the manager discouraged them from commanding: "Sometimes you need someone to galvanise and that might be a shouter and bawler. It may not be Arsene's way, but I think they lack that." Wenger is perceived as frugal given his inactivity in transfer windows, but he has denied the stereotype: "Of course people say always to buy but you cannot make careers [and you cannot] buy every time you have an injured player. You know I have the wrong reputation. I'm not scared to spend money.
The Wall Street Journal reported that several US Navy destroyers entered the Strait of Hormuz for the first time since the war began. A US official described the event as an "operation that focused on freedom of navigation through International waters”. Iranian government reportedly threatened to attack the ships, accusing US of ceasefire violation. US CENTCOM said the ships are taking part in mine clearance operations. JD Vance announced that the talks between the US and Iran had failed, as he was unable to reach an agreement after a day of negotiations. Afterwards, Trump declared a naval blockade on the Strait of Hormuz, announcing that the US Navy will prevent ships from entering or exiting the Strait and intercept vessels that have paid tolls to Iran. US CENTCOM announced that the blockade will be enforced on vessels of all nations entering or departing Iranian ports and coastal areas but "will not impede freedom of navigation for vessels transiting the Strait of Hormuz to and from non-Iranian ports." The IRGC Navy said that any military vessel approaching the strait would be considered a ceasefire violation and would meet a "severe response." On 21 April, US Senator Lindsey Graham praised the decision to leave the naval blockade in place, saying that it will be a source of pressure for the Iranian government. He also set out strict conditions for any potential agreement with Iran. On 12 May, ahead of his state visit to China, Trump was asked by a reporter about the extent to which he cared about Americans' financial situations while in negotiations with Iran.
Sources: en.wikipedia.org
Purves, Dale; Augustine, George J.; Fitzpatrick, David; Katz, Lawrence C.; LaMantia, Anthony-Samuel; McNamara, James O.; Williams, S. Mark (2001). "Chapter 6. Neurotransmitters". What Defines a Neurotransmitter? (2nd ed.). Sunderland (MA): Sinauer Associates. ISBN 0-87893-742-0. Holz, Ronald W.; Fisher, Stephen K. (1999). "Chapter 10. Synaptic Transmission and Cellular Signaling: An Overview". In Siegel, George J; Agranoff, Bernard W; Albers, R Wayne; Fisher, Stephen K; Uhler, Michael D (eds.). Basic Neurochemistry: Molecular, Cellular and Medical Aspects (6th ed.). Philadelphia: Lippincott-Raven. ISBN 0-397-51820-X. Neurotransmitters and Neuroactive Peptides at Neuroscience for Kids website
==== By activase ==== The removal of the inhibitory RuBP, CA1P, and the other inhibitory substrate analogs by activase requires the consumption of ATP. This reaction is inhibited by the presence of ADP, and, thus, activase activity depends on the ratio of these compounds in the chloroplast stroma. Furthermore, in most plants, the sensitivity of activase to the ratio of ATP/ADP is modified by the stromal reduction/oxidation (redox) state through another small regulatory protein, thioredoxin. In this manner, the activity of activase and the activation state of RuBisCO can be modulated in response to light intensity and, thus, the rate of formation of the ribulose 1,5-bisphosphate substrate.
They include reverse transcriptase, which is a viral enzyme involved in the infection of cells by retroviruses, and telomerase, which is required for the replication of telomeres. For example, HIV reverse transcriptase is an enzyme for AIDS virus replication. Telomerase is an unusual polymerase because it contains its own RNA template as part of its structure. It synthesizes telomeres at the ends of chromosomes. Telomeres prevent fusion of the ends of neighboring chromosomes and protect chromosome ends from damage. Transcription is carried out by a DNA-dependent RNA polymerase that copies the sequence of a DNA strand into RNA. To begin transcribing a gene, the RNA polymerase binds to a sequence of DNA called a promoter and separates the DNA strands. It then copies the gene sequence into a messenger RNA transcript until it reaches a region of DNA called the terminator, where it halts and detaches from the DNA. As with human DNA-dependent DNA polymerases, RNA polymerase II, the enzyme that transcribes most of the genes in the human genome, operates as part of a large protein complex with multiple regulatory and accessory subunits.
Andress, Jason. Winterfeld, Steve. (2011). Cyber Warfare: Techniques, Tactics and Tools for Security Practitioners. Syngress. ISBN 1-59749-637-5 Bodmer, Kilger, Carpenter, & Jones (2012). Reverse Deception: Organized Cyber Threat Counter-Exploitation. New York: McGraw-Hill Osborne Media. ISBN 0-07-177249-9, "ISBN 978-0-07-177249-5" Brenner, S. (2009). Cyber Threats: The Emerging Fault Lines of the Nation State. Oxford University Press. ISBN 0-19-538501-2 Carr, Jeffrey. (2010). Inside Cyber Warfare: Mapping the Cyber Underworld. O'Reilly. ISBN 978-0-596-80215-8 Conti, Gregory. Raymond, David. (2017). On Cyber: Towards an Operational Art for Cyber Conflict. Kopidion Press. ISBN 978-0-692-91156-3 Cordesman, Anthony H.; Cordesman, Justin G. (2002). Cyber-threats, Information Warfare, and Critical Infrastructure Protection: Defending the U.S. Homeland. Greenwood Publishing Group. ISBN 978-0-275-97423-7. Costigan, Sean S.; Perry, Jake (2012). Cyberspaces and global affairs. Farnham, Surrey: Ashgate. ISBN 978-1-4094-2754-4. Fritsch, Lothar & Fischer-Hübner, Simone (2019). Implications of Privacy & Security Research for the Upcoming Battlefield of Things. Journal of Information Warfare, 17(4), 72–87. Gaycken, Sandro. (2012). Cyberwar – Das Wettrüsten hat längst begonnen. Goldmann/Randomhouse. ISBN 978-3-442-15710-5 Geers, Kenneth. (2011). Strategic Cyber Security. NATO Cyber Centre.
=== Gr–Gu === Sam Granick (1909–1977). American biochemist at the Rockefeller University, known for his studies of ferritin and iron metabolism. Member Natl. Acad. Sci. USA. David E. Green (1910–1983). American biochemist at the University of Wisconsin, pioneer in the study of enzymes involved in oxidative phosphorylation. Member Natl. Acad. Sci. USA. Rowena Green Matthews (b. 1938). American biochemist at the University of Michigan Ann Arbor, working on the role of organic cofactors of enzymes, especially folic acid and cobalamin. Member Natl. Acad. Sci. USA. Lewis Joel Greene (b. 1934), American-Brazilian biochemist at the University of São Paulo, known for studies of protein chemistry. François Gros (1925–2022). French biologist and pioneer of cellular biochemistry at the French Academy of Sciences. Kun-Liang Guan (b. 1963). Chinese-American biochemist at the University of Michigan who works on gene regulation. F. Peter Guengerich (b. 1949). Biochemist and toxicologist at Vanderbilt University, working on cytochromes P450, DNA damage and carcinogenesis, and drug metabolism. Note. His personal Wikipedia page is very uninformative. Joan Guinovart (1947–2025). Spanish biochemist at the Institute for Research in Biomedicine (IRB Barcelona) known for studies of glycogen. Irwin Gunsalus (1912–2008). American biochemist at the University of Illinois, who discovered lipoic acid. He coauthored The Bacteria: A Treatise on Structure and Function with Roger Y. Stanier, a highly influential five-volume work. Member Natl. Acad. Sci. USA. Herbert Gutfreund FRS (1921–2021).
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.